A detailed history of Bank Of America Corp transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Bank Of America Corp holds 118,618 shares of SGMO stock, worth $230,118. This represents 0.0% of its overall portfolio holdings.

Number of Shares
118,618
Previous 158,231 25.03%
Holding current value
$230,118
Previous $56,000 82.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.32 - $1.1 $12,676 - $43,574
-39,613 Reduced 25.03%
118,618 $102,000
Q2 2024

Aug 14, 2024

SELL
$0.36 - $0.65 $39,898 - $72,038
-110,829 Reduced 41.19%
158,231 $56,000
Q1 2024

May 15, 2024

BUY
$0.42 - $1.38 $16,071 - $52,807
38,266 Added 16.58%
269,060 $180,000
Q4 2023

Feb 14, 2024

SELL
$0.3 - $0.63 $48,883 - $102,654
-162,944 Reduced 41.38%
230,794 $124,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $1.74 $859,132 - $1.35 Million
-773,993 Reduced 66.28%
393,738 $511,000
Q1 2023

May 12, 2023

BUY
$1.66 - $3.67 $89,708 - $198,330
54,041 Added 4.85%
1,167,731 $2.06 Million
Q4 2022

Feb 10, 2023

BUY
$2.77 - $5.07 $959,375 - $1.76 Million
346,345 Added 45.14%
1,113,690 $3.5 Million
Q3 2022

Nov 14, 2022

BUY
$4.27 - $6.39 $291,538 - $436,283
68,276 Added 9.77%
767,345 $3.76 Million
Q2 2022

Aug 12, 2022

SELL
$3.28 - $6.21 $146,497 - $277,363
-44,664 Reduced 6.01%
699,069 $2.89 Million
Q1 2022

May 16, 2022

BUY
$5.23 - $7.82 $1.65 Million - $2.47 Million
315,942 Added 73.85%
743,733 $4.32 Million
Q4 2021

Feb 08, 2022

SELL
$7.29 - $10.97 $216,287 - $325,468
-29,669 Reduced 6.49%
427,791 $3.21 Million
Q3 2021

Nov 15, 2021

BUY
$9.01 - $12.01 $895,359 - $1.19 Million
99,374 Added 27.75%
457,460 $4.12 Million
Q2 2021

Sep 13, 2021

BUY
$10.17 - $12.64 $3.64 Million - $4.53 Million
358,086 New
358,086 $4.29 Million

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $304M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.